US 11,707,612 B2
Intelligent bioelectric module for use with drug delivery system
Michael Motion, San Jose, CA (US); Michel M. Maharbiz, El Cerrito, CA (US); and Russell Potts, San Francisco, CA (US)
Assigned to Bioelectric Devices, Inc., Menlo Park, CA (US)
Filed by Bioelectric Devices, Inc., Menlo Park, CA (US)
Filed on Sep. 28, 2020, as Appl. No. 17/34,474.
Application 17/034,474 is a division of application No. 15/661,813, filed on Jul. 27, 2017, granted, now 10,842,979.
Claims priority of provisional application 62/399,284, filed on Sep. 23, 2016.
Claims priority of provisional application 62/367,711, filed on Jul. 28, 2016.
Prior Publication US 2021/0023353 A1, Jan. 28, 2021
Int. Cl. A61N 1/30 (2006.01); A61M 35/00 (2006.01)
CPC A61M 35/00 (2013.01) [A61M 2205/3303 (2013.01); A61M 2205/3317 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/52 (2013.01); A61M 2205/6072 (2013.01); A61M 2230/04 (2013.01)] 4 Claims
OG exemplary drawing
 
1. An intelligent bioelectric module for use with a drug delivery system, the drug delivery system having first and second surface regions, wherein the first surface region is configured for contact with a tissue surface of a human or animal subject, the module comprising:
a case;
a set of at least two electrodes in electrical communication with a detection surface of the case, wherein a set of dielectric materials is disposed between the detection surface and the electrodes;
wherein the case is configured so that, in use, the detection surface comes into electrical communication with a member selected from the group consisting of (i) the second surface region of the drug delivery system, (ii) the tissue surface that is adjacent to a portion contacted by the first surface region of the drug delivery system, and (iii) combinations thereof; and
electronics disposed within the case that determines if a quantity related to impedance to an AC signal is within a predetermined limit, wherein the impedance to the AC signal is experienced over a path that includes (a) the set of electrodes and (b) material in a location selected from the group consisting of the second surface region, the tissue surface, and combinations thereof;
wherein, if the impedance to the AC signal is determined to be within the predetermined limit, the drug delivery system is determined to be coupled to tissue as opposed to non-living material.